

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cyclo Spray, Chlortetracycline HCl 2.45 % w/w, cutaneous spray, suspension for pigs, sheep and cattle

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active substance:

Chlortetracycline HCl.

The active ingredient content is 2.45 % w/w.

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Patent Blue V (E 131), colouring agent	0.15 % w/w
Butane 100, propellant	68.77 % w/w
Colloidal anhydrous silica (Aerosil 200)	
Isopropyl alcohol	
Sorbitan trioleate (Span 85)	

Blue coloured spray.

3. CLINICAL INFORMATION

3.1 Target species

Cattle, sheep and pigs.

3.2 Indications for use for each target species

- Prevention of infections of superficial traumatic or surgical wounds caused by micro-organisms sensitive to chlortetracycline.
- The veterinary medicinal product can be used as part of a treatment for superficial claw/hoof infections, in particular interdigital dermatitis (foot rot) in sheep and digital dermatitis in cattle.

3.3 Contraindications

Do not use in case of hypersensitivity to tetracyclines or to any of the excipients.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Protect the eyes when spraying in the vicinity of the head. Clean the affected area thoroughly before spraying. Treatment of foot conditions should always be preceded by appropriate paring of the hoof, as this is critical for achieving an adequate response. After spraying the feet, the animal should be kept on dry ground for at least one hour. The animal should be discouraged from licking the treated area, or treated areas on other animals.

Use of the veterinary medicinal product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at farm level, or at local/regional level. Use of the product should be in accordance with official, national and regional antimicrobial policies.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Direct contact with the skin should be avoided because of sensitisation, contact dermatitis and possible hypersensitivity reactions to chlortetracycline. Wear appropriate impermeable gloves whilst handling the veterinary medicinal product.

Because of risk of eye irritation, contact with the eyes should be avoided. Protect the eyes and face.

Do not spray on an open flame or other ignition source. Do not pierce or burn, even after use.

Avoid inhaling vapours. Apply the veterinary medicinal product in open air or in sufficiently ventilated area.

Wash hands after use.

Do not eat or smoke whilst administering the veterinary medicinal product.

In case of accidental ingestion or in case of contact with eyes, seek medical advice immediately and show the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cattle, sheep and pigs:

Rare (1 to 10 animals / 10,000 animals treated):	Hypersensitivity reaction
---	---------------------------

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Lactation:

Following cutaneous administration of the veterinary medicinal product, absorption of chlortetracycline is negligible and it is not detectable in the milk.

3.8 Interaction with other medicinal products and other forms of interaction

After cutaneous administration of chlortetracycline spray, absorption of chlortetracycline is negligible. No data on interactions with other local treatments are available.

3.9 Administration routes and dosage

Cutaneous use.

Shake the container thoroughly before spraying. The container should be held at a distance of 15-20 cm from the area to be sprayed; spray for approximately 3 seconds (equivalent to approximately 3.9 g of product or 0.10 g chlortetracycline) until the treatment-area is evenly coloured. In case of claw/hoof infections this treatment should be repeated after 30 seconds.

- For prevention of infections after superficial traumatic or surgical wounds a single administration is recommended.
- For treatment of Dermatitis Digitalis, a double administration (with a 30 second interval) is recommended daily for three consecutive days.
- For treatment of other hoof infections (foot rot), a double administration (with a 30 second interval) is recommended. Dependent on the seriousness of the injury and the rate of improvement treatment should be repeated within 1 to 3 days

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Meat and offal: zero days

Milk: zero days

Do not use on the udder of lactating animals if milk is intended for human consumption. Stained part of the pigskin must be removed prior to the rest of the animal being used for human consumption.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code:

QD06AA02.

4.2 Pharmacodynamics

In vitro, chlortetracycline is primarily bacteriostatic. Chlortetracycline exerts its action by inhibiting the protein synthesis of the bacterial cell. Especially cell division and the formation of the cell wall are impaired. Chlortetracycline binds to receptors on the 30S-subunit of the bacterial ribosome where they interfere with the binding of the aminoacyl-transfer RNA to the acceptor site on the messenger RNA ribosome complex.

4.3 Pharmacokinetics

Following cutaneous administration of chlortetracycline spray, chlortetracycline absorption is negligible. Therefore the veterinary medicinal product will only have a local effect, no systemic effects are to be anticipated.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years

5.3 Special precautions for storage

Extremely flammable aerosol. Pressurized container: May burst if heated. Protect from sunlight. Do not expose to temperatures exceeding 50 °C. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.

5.4 Nature and composition of immediate packaging

A 270 ml pressurized container of coated tin plate with a plastic valve mechanism and spraying nozzle containing 130.76 g of product.

A 520 ml pressurized container of coated tin plate with a plastic valve mechanism and spraying nozzle containing 261.52 g of product.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Eurovet Animal Health B.V.

7. MARKETING AUTHORISATION NUMBER

Vm 16849/4002

8. DATE OF FIRST AUTHORISATION

14 August 2006

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

October 2025

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

Gavin Hall

Approved: 14 January 2026